Merck – Talk Bio

Merck Advances Middle Dose of ROR1 ADC in Relapsed/Refractory DLBCL After Safety Review

1 week ago talkbio0Tagged Adverse event, Clinical Trials, Diffuse Large B-Cell Lymphoma, Merck, middle dose, Relapsing course, ROR1 protein, human, Safety, therapeutic autologous dendritic cells, Unresponsive to Treatment, vedotin, waveLINE-003, Zilovertamab

Merck; ROR1; ADC; zilovertamab vedotin; middle dose; 1.75 mg/kg; relapsed DLBCL; refractory DLBCL; WaveLINE-003; safety; adverse events; clinical trial; ASCO 2025

Merck, Daiichi Sankyo Withdraw FDA Application for HER3-Targeting ADC After Survival Endpoint Miss

2 weeks ago talkbio0Tagged Application procedure, Clinical Trials, Daiichi, Deruxtecan, HER3, Merck, Non-Small Cell Lung Carcinoma, Overall Survival, patritumab, Sankyo, therapeutic autologous dendritic cells, United States Food and Drug Administration, Withdraw (activity)

Merck; Daiichi Sankyo; patritumab deruxtecan; HER3 ADC; FDA application; non-small cell lung cancer; clinical trial; overall survival; application withdrawal

Merck’s Keytruda Achieves Industry-First Success in Preventing Head and Neck Cancer Recurrence: AACR 2025 Highlights

4 weeks ago talkbio0Tagged AACR, Cancer of Neck, Clinical Trials, Event-Free Survival, Head, KEYNOTE-689 trial, Keytruda, locally advanced head, Merck, pembrolizumab, perioperative, recurrence prevention, Squamous cell carcinoma, United States Food and Drug Administration

Keytruda; Merck; AACR 2025; head and neck cancer; resectable locally advanced head and neck squamous cell carcinoma; event-free survival; KEYNOTE-689 trial; perioperative pembrolizumab; recurrence prevention; clinical trial; FDA

Merck & Co. breaks ground on $1B future US home of Keytruda

1 month ago talkbio0Tagged Biological Factors, Home environment, Keytruda, Merck, United States, Wilmington

United States, Keytruda, Home environment, Merck, Wilmington, Biological Factors

Merck KGaA closes in on SpringWorks deal at $3.5B price point

1 month ago talkbio0Tagged Acquisition (action), deal, Gomekli, Infrequent, KGaA, Merck, SpringWorks

SpringWorks, Acquisition (action), KGaA, Infrequent, Gomekli, deal, Merck

Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through

1 month ago talkbio0Tagged Halozyme, Legal patent, Merck, Subcutaneous Keytruda

Merck, Legal patent, Subcutaneous Keytruda, Halozyme

Merck inks $493M biobucks deal to use Cyprumed’s tech to create oral peptides

2 months ago talkbio0Tagged biobucks, Cyprumed, Merck, Peptides

Cyprumed, Merck, biobucks, Peptides

The 5 Largest Biopharma Layoffs of Q1 2025: An Overview of Industry Restructuring

2 months ago talkbio0Tagged 2025, Biopharma layoffs, Drug Industry, Galapagos layoffs, Gilead, Industry, losses, Merck, Myers, Novartis, Q1 2025, restructuring, Squibb Layoffs, trends qualifier

Biopharma layoffs 2025, Novartis layoffs, Galapagos layoffs, Bristol Myers Squibb layoffs, Merck cuts, Gilead workforce reduction, Q1 2025 job cuts, biotech restructuring, pharmaceutical industry job losses, industry trends.